

Pieter Sonneveld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2781738/publications.pdf>

Version: 2024-02-01

333
papers

31,994
citations

9234

74
h-index

4419

172
g-index

337
all docs

337
docs citations

337
times ranked

17629
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 127-134.	0.7	4
2	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
3	VS38c and CD38-Multipeptide Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma. <i>American Journal of Clinical Pathology</i> , 2022, 157, 494-497.	0.4	8
4	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. <i>American Journal of Hematology</i> , 2022, 97, 481-490.	2.0	6
5	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	2.2	32
6	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. <i>BMC Cancer</i> , 2022, 22, 147.	1.1	1
7	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 820768.	1.3	5
8	Treatment emergent peripheral neuropathy in the CASSIOPEIA trial. <i>Haematologica</i> , 2022, 107, 1726-1730.	1.7	2
9	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3150.	0.8	13
10	Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. <i>Blood Cancer Journal</i> , 2022, 12, 41.	2.8	6
11	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	3.3	81
12	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	0.8	115
13	Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. <i>Leukemia</i> , 2022, 36, 1887-1897.	3.3	23
14	Standardization of ¹⁸ F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	0.8	85
15	Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D+VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching. <i>EJHaem</i> , 2021, 2, 66-80.	0.4	0
16	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
17	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	3.3	35
18	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 1.	2.8	57

#	ARTICLE	IF	CITATIONS
19	First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. <i>Blood Cancer Journal</i> , 2021, 11, 22.	2.8	5
20	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. <i>British Journal of Haematology</i> , 2021, 193, 561-569.	1.2	10
21	Improving the identification of frail elderly newly diagnosed multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 2715-2719.	3.3	5
22	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
23	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
24	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3695-3703.	3.2	7
25	V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2219.	1.7	7
26	The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. <i>Nature Immunology</i> , 2021, 22, 769-780.	7.0	107
27	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	2.8	31
28	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. <i>American Journal of Hematology</i> , 2021, 96, 896-900.	2.0	12
29	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 801-812.	5.1	162
30	Perspectives on returning to work of multiple myeloma patients: A qualitative interview study. <i>European Journal of Cancer Care</i> , 2021, 30, e13481.	0.7	6
31	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2758-2767.	0.8	25
32	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
33	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. <i>Haematologica</i> , 2021, 106, 1496-1499.	1.7	9
34	Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5128-5139.	2.5	22
35	High Levels of Circulating Tumor Cells Are Associated with Increased Bone Marrow Proliferation in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2021, 138, 1566-1566.	0.6	0
36	Inflammasome-Primed Myeloid Cells Maintain a Pro-Tumor Microenvironment in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2679-2679.	0.6	1

#	ARTICLE	IF	CITATIONS
37	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. Blood, 2021, 138, 2732-2732.	0.6	0
38	Single-Cell Transcriptomic Analysis Reveals Loss of Activated Bone Marrow NK Cells in Multiple Myeloma Patients Which Associates with Disease Progression in Mice. Blood, 2021, 138, 1578-1578.	0.6	0
39	Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic. Blood, 2021, 138, 1657-1657.	0.6	0
40	Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial. Blood, 2021, 138, 1664-1664.	0.6	6
41	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status. Blood, 2021, 138, 4779-4779.	0.6	0
42	Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer Journal, 2021, 11, 178.	2.8	6
43	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	2.8	62
44	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica, 2020, 105, 193-200.	1.7	29
45	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica, 2020, 105, 1650-1659.	1.7	19
46	The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia and Lymphoma, 2020, 61, 680-690.	0.6	9
47	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 509-518.	0.2	91
48	Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice. HemaSphere, 2020, 4, e366.	1.2	5
49	Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematology, the, 2020, 7, e874-e883.	2.2	20
50	Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. HemaSphere, 2020, 4, e370.	1.2	2
51	Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. EJHaem, 2020, 1, 481-488.	0.4	0
52	Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 5952-5961.	3.2	5
53	Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. Blood Advances, 2020, 4, 6298-6309.	2.5	22
54	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. Blood Cancer Journal, 2020, 10, 58.	2.8	9

#	ARTICLE	IF	CITATIONS
55	Search for multiple myeloma risk factors using Mendelian randomization. <i>Blood Advances</i> , 2020, 4, 2172-2179.	2.5	27
56	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	1.0	34
57	Early Mâ€Protein Dynamics Predicts Progressionâ€Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical and Translational Science</i> , 2020, 13, 1345-1354.	1.5	7
58	Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. <i>Leukemia</i> , 2020, 34, 1964-1966.	3.3	22
59	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€melphalanâ€prednisone, with or without bortezomibâ€lenalidomideâ€dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2020, 7, e456-e468.	2.2	244
60	EHA evaluation of the ESMOâ€Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
61	Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplishedâ€What is Next?. <i>HemaSphere</i> , 2020, 4, e354.	1.2	0
62	Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma?. <i>Lancet Haematology</i> , the, 2020, 7, e445-e446.	2.2	2
63	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
64	Peripheral Neuropathy in the Cassiopeia Study. <i>Blood</i> , 2020, 136, 48-48.	0.6	1
65	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	0.6	16
66	Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95). <i>Blood</i> , 2020, 136, 46-48.	0.6	4
67	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	0.6	12
68	EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in Hematology. <i>HemaSphere</i> , 2020, 4, e365.	1.2	1
69	Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001. <i>Blood</i> , 2020, 136, 8-9.	0.6	4
70	The Prognostic Power of Gene Expression Profiling with Cytogenetics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
71	High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling. <i>Blood</i> , 2020, 136, 23-24.	0.6	1
72	Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations. <i>Blood</i> , 2020, 136, 9-10.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis. <i>Blood</i> , 2020, 136, 11-12.	0.6	1
74	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019, 33, 159-170.	3.3	313
75	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 240.	0.7	22
76	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	1.7	7
77	High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. <i>Blood</i> , 2019, 133, 1217-1221.	0.6	79
78	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	0.8	39
79	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 29-38.	6.3	665
80	Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. <i>Haematologica</i> , 2019, 104, 2265-2273.	1.7	23
81	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282.	1.7	27
82	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33
83	Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. <i>Blood Advances</i> , 2019, 3, 4202-4214.	2.5	60
84	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	1.7	18
85	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. <i>Cancer</i> , 2019, 125, 750-760.	2.0	31
86	A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 151-162.	0.6	8
87	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
88	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study. <i>Blood</i> , 2019, 134, 695-695.	0.6	14
89	Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220). <i>Blood</i> , 2019, 134, 3119-3119.	0.6	17
90	Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study. <i>Blood</i> , 2019, 134, 1879-1879.	0.6	9

#	ARTICLE	IF	CITATIONS
91	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	0.6	18
92	Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset. <i>Blood</i> , 2019, 134, 2130-2130.	0.6	1
93	Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8055-TPS8055.	0.8	31
94	Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials. <i>Blood</i> , 2019, 134, 1798-1798.	0.6	0
95	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , 2018, 32, 1803-1807.	3.3	39
96	Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. <i>Pharmacogenomics</i> , 2018, 19, 213-226.	0.6	3
97	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
98	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. <i>Haematologica</i> , 2018, 103, e368-e371.	1.7	43
99	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
100	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2035-2043.	0.8	55
101	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	1.7	225
102	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , 2018, 5, e479-e492.	2.2	25
103	Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. <i>Advances in Therapy</i> , 2018, 35, 1859-1872.	1.3	23
104	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	5.8	86
105	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. <i>Blood</i> , 2018, 132, 2154-2165.	0.6	14
106	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
107	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Blood Advances</i> , 2018, 2, 2400-2411.	2.5	5
108	Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. <i>Nature Communications</i> , 2018, 9, 2943.	5.8	23

#	ARTICLE	IF	CITATIONS
109	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81
110	Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. <i>Molecular Pain</i> , 2018, 14, 174480691879704.	1.0	26
111	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
112	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018, 132, 587-597.	0.6	335
113	Long-term Outcomes in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2018, 2, e45.	1.2	38
114	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	0.6	20
115	Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial. <i>Blood</i> , 2018, 132, 800-800.	0.6	6
116	Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimism Trial. <i>Blood</i> , 2018, 132, 3278-3278.	0.6	5
117	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor. <i>Blood</i> , 2018, 132, 3270-3270.	0.6	6
118	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. <i>Blood</i> , 2018, 132, 3288-3288.	0.6	10
119	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	0.6	41
120	Carfilzomib, Pomalidomide and Dexamethasone (Kpd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial. <i>Blood</i> , 2018, 132, 801-801.	0.6	26
121	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study. <i>Blood</i> , 2018, 132, 596-596.	0.6	19
122	Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) – Results of the Dutch HOVON 123 Study. <i>Blood</i> , 2018, 132, 1889-1889.	0.6	11
123	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	0.6	3
124	Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 8019-8019.	0.8	8
125	Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8059-TPS8059.	0.8	8
126	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 34009-34021.	0.8	17

#	ARTICLE	IF	CITATIONS
127	Treatment of t(4;14) and del(17p) in Multiple Myeloma. , 2018, , 59-76.		0
128	Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal. Blood, 2018, 132, 4485-4485.	0.6	0
129	Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse. Blood, 2018, 132, 3157-3157.	0.6	0
130	MCL-1 Inhibition Is Highly Effective Against Multiple Myeloma Cells from Poor Prognosis Patients. Blood, 2018, 132, 1916-1916.	0.6	0
131	Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells. Blood, 2018, 132, 241-241.	0.6	0
132	How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. Critical Reviews in Oncology/Hematology, 2017, 112, 153-170.	2.0	37
133	Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma. Haematologica, 2017, 102, e317-e320.	1.7	27
134	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology, 2017, 178, 547-560.	1.2	48
135	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood, 2017, 129, 456-459.	0.6	62
136	Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Lancet Haematology, the, 2017, 4, e443-e451.	2.2	20
137	MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands. Cancer Epidemiology, 2017, 50, 137-140.	0.8	4
138	Multiple myeloma. Nature Reviews Disease Primers, 2017, 3, 17046.	18.1	812
139	Should minimal residual disease negativity not be the end point of myeloma therapy?. Blood Advances, 2017, 1, 522-525.	2.5	5
140	Management of multiple myeloma in the relapsed/refractory patient. Hematology American Society of Hematology Education Program, 2017, 2017, 508-517.	0.9	65
141	Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clinical Pharmacology: Advances and Applications, 2017, Volume 9, 133-145.	0.8	10
142	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. Journal of Clinical Oncology, 2017, 35, 8006-8006.	0.8	18
143	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. Journal of Clinical Oncology, 2017, 35, 8011-8011.	0.8	15
144	Daratumumab, bortezomib and dexamethasone (DVD) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. Journal of Clinical Oncology, 2017, 35, 8036-8036.	0.8	4

#	ARTICLE	IF	CITATIONS
145	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	2.0	40
146	A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. <i>European Journal of Haematology</i> , 2016, 96, 198-208.	1.1	33
147	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2016, 128, 2297-2306.	0.6	49
148	Treatment of relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 396-406.	1.7	132
149	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 4350-4355.	3.2	38
150	Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. <i>Haematologica</i> , 2016, 101, e149-e152.	1.7	6
151	Innovations in treatment and response evaluation in multiple myeloma. <i>Haematologica</i> , 2016, 101, 518-520.	1.7	2
152	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	0.6	179
153	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. <i>Blood</i> , 2016, 127, 1109-1116.	0.6	102
154	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
155	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. <i>Blood</i> , 2016, 128, 959-970.	0.6	286
156	Costs of haematological disease high and rising. <i>Lancet Haematology</i> , 2016, 3, e353-e354.	2.2	10
157	Prevalence of potential underlying aetiology of macrocytic anaemia in Dutch general practice. <i>BMC Family Practice</i> , 2016, 17, 113.	2.9	13
158	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	13.9	1,246
159	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , 2016, 17, e328-e346.	5.1	1,866
160	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	5.8	146
161	Impact of Genes Highly Correlated with <i>MMSET</i> Myeloma on the Survival of Non- <i>MMSET</i> Myeloma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 4039-4044.	3.2	14
162	Cytokine and viral load kinetics in human herpesvirus 8-associated multicentric Castleman's disease complicated by hemophagocytic lymphohistiocytosis. <i>International Journal of Hematology</i> , 2016, 103, 469-472.	0.7	6

#	ARTICLE	IF	CITATIONS
163	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. Blood, 2016, 128, 1141-1141.	0.6	7
164	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. Blood, 2016, 128, 1145-1145.	0.6	6
165	The Relationship of Response on Time to Next Treatment Based on Evidence from Two RCTs in Newly Diagnosed Stem Cell Transplantation Ineligible Multiple Myeloma Patients. Blood, 2016, 128, 2141-2141.	0.6	2
166	Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients. Blood, 2016, 128, 2144-2144.	0.6	2
167	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood, 2016, 128, 242-242.	0.6	26
168	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. Blood, 2016, 128, 2957-2957.	0.6	1
169	Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study. Blood, 2016, 128, 3305-3305.	0.6	4
170	Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor. Blood, 2016, 128, 3313-3313.	0.6	5
171	Carfilzomib in Combination with Bendamustine and Dexamethasone (CbD) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. Blood, 2016, 128, 3334-3334.	0.6	5
172	Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy. Blood, 2016, 128, 3340-3340.	0.6	1
173	HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed AL Amyloidosis. Blood, 2016, 128, 4628-4628.	0.6	1
174	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2016, 128, 646-646.	0.6	37
175	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood, 2016, 128, 673-673.	0.6	29
176	Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95) Tj ETQq0 0.0 rgBT / 00erlock 10	0.6	0
177	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. Journal of Clinical Oncology, 2016, 34, 8000-8000.	0.8	52
178	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (Dvd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. Journal of Clinical Oncology, 2016, 34, LBA4-LBA4.	0.8	5
179	A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2016, 34, TPS8072-TPS8072.	0.8	2
180	Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (Dvd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.. Journal of Clinical Oncology, 2016, 34, LBA4-LBA4.	0.8	13

#	ARTICLE	IF	CITATIONS
181	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. <i>Blood</i> , 2016, 128, 2072-2072.	0.6	1
182	Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis. <i>Blood</i> , 2016, 128, 3271-3271.	0.6	2
183	Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012. <i>British Journal of Haematology</i> , 2015, 171, 436-439.	1.2	7
184	Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. <i>European Journal of Haematology</i> , 2015, 95, 316-324.	1.1	33
185	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, 100-106.	1.7	33
186	Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, e63-e67.	1.7	22
187	Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 449-456.	0.6	60
188	Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. <i>Blood</i> , 2015, 126, 1996-2004.	0.6	106
189	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
190	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. <i>Haematologica</i> , 2015, 100, 677-682.	1.7	18
191	Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival. <i>Haematologica</i> , 2015, 100, e508-e510.	1.7	10
192	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 519-530.	0.2	40
193	The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. <i>Leukemia Research</i> , 2015, 39, 177-182.	0.4	39
194	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	0.8	330
195	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	0.8	1,525
196	Chemotherapy-induced peripheral neuropathies in hematological malignancies. <i>Journal of Neuro-Oncology</i> , 2015, 121, 229-237.	1.4	37
197	A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. <i>Leukemia and Lymphoma</i> , 2015, 56, 594-601.	0.6	7
198	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146

#	ARTICLE	IF	CITATIONS
199	Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations. <i>JAMA Oncology</i> , 2015, 1, 754.	3.4	0
200	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. <i>Blood</i> , 2015, 126, 1828-1828.	0.6	4
201	Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. <i>Blood</i> , 2015, 126, 27-27.	0.6	28
202	The Combination of SKY92 and ISS Provides a Powerful Tool to Identify Both High Risk and Low Risk Multiple Myeloma Cases, Validation in Two Independent Cohorts. <i>Blood</i> , 2015, 126, 2970-2970.	0.6	6
203	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , 2015, 126, 3029-3029.	0.6	1
204	Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis. <i>Blood</i> , 2015, 126, 374-374.	0.6	6
205	Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor). <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8609-TPS8609.	0.8	5
206	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	1.1	10
207	The Sense and Nonsense of Anaemia Analysis in Relation to Mortality in General Practice. <i>Blood</i> , 2015, 126, 4549-4549.	0.6	0
208	Targeted Genomic Mutation Panel (M3 P) Results from 504 Multiple Myeloma (MM) Patients. <i>Blood</i> , 2015, 126, 1795-1795.	0.6	0
209	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. <i>Blood</i> , 2015, 126, 4173-4173.	0.6	0
210	RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response. <i>Blood</i> , 2015, 126, 2969-2969.	0.6	0
211	Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 2967-2967.	0.6	0
212	M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma. <i>Blood</i> , 2015, 126, 2984-2984.	0.6	0
213	Identification and Validation of IMiD-14 Model Predictive of IMiD Resistance in Multiple Myeloma. <i>Blood</i> , 2015, 126, 4183-4183.	0.6	0
214	Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study. <i>Blood</i> , 2015, 126, 1760-1760.	0.6	1
215	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	1.7	124
216	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	1.7	185

#	ARTICLE	IF	CITATIONS
217	Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. <i>European Journal of Cancer</i> , 2014, 50, 1004-1012.	1.3	55
218	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	5.1	256
219	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
220	Cancer-Selective Targeting of the NF- κ B Survival Pathway with GADD45 β /MKK7 Inhibitors. <i>Cancer Cell</i> , 2014, 26, 495-508.	7.7	99
221	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	1.9	90
222	Diagnosis and Risk Stratification in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 791-813.	0.9	19
223	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.	0.8	150
224	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	0.6	126
225	Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. <i>Haematologica</i> , 2014, 99, 148-154.	1.7	113
226	Age and aging in blood disorders: multiple myeloma. <i>Haematologica</i> , 2014, 99, 1133-1137.	1.7	50
227	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. <i>Blood</i> , 2014, 124, 175-175.	0.6	4
228	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	0.6	0
229	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 3279-3287.	0.8	238
230	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1055-1066.	5.1	710
231	High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. <i>Blood</i> , 2013, 121, 624-627.	0.6	114
232	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	1.7	193
233	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. <i>Haematologica</i> , 2013, 98, 87-94.	1.7	73
234	No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study. <i>Blood</i> , 2013, 122, 2132-2132.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study). <i>Blood</i> , 2013, 122, 287-287.	0.6	2
236	Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification. <i>Blood</i> , 2013, 122, 3092-3092.	0.6	3
237	Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 3187-3187.	0.6	14
238	Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial. <i>Blood</i> , 2013, 122, 3332-3332.	0.6	2
239	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	0.6	17
240	A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 685-685.	0.6	8
241	One Line Does Not Make a Picture: Real-World Cost-Effectiveness Of Multiple Myeloma Treatments Using a Full Disease Model. <i>Blood</i> , 2013, 122, 2930-2930.	0.6	0
242	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.	1.9	48
243	Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. <i>Haematologica</i> , 2012, 97, 1272-1277.	1.7	254
244	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2946-2955.	0.8	735
245	Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. <i>Blood</i> , 2012, 119, 940-948.	0.6	327
246	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
247	Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate. <i>Blood</i> , 2012, 120, 333-333.	0.6	9
248	A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation. <i>Blood</i> , 2012, 120, 4055-4055.	0.6	2
249	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. <i>Blood</i> , 2012, 120, 749-749.	0.6	8
250	Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8095-8095.	0.8	9
251	Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial. <i>Blood</i> , 2012, 120, 1853-1853.	0.6	0
252	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 44-49.	0.2	38

#	ARTICLE	IF	CITATIONS
253	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2011, 37, 266-283.	3.4	66
254	Bortezomib-induced peripheral neuropathy: facts and genes – Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 121.	5.1	0
255	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , 2011, 118, 1239-1247.	0.6	243
256	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	0.6	247
257	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	0.6	285
258	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
259	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	0.6	309
260	Cytarabine Dose for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 1027-1036.	13.9	343
261	Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia. <i>Blood</i> , 2011, 118, 2758-2758.	0.6	1
262	Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2933-2933.	0.6	5
263	A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,. <i>Blood</i> , 2011, 118, 3971-3971.	0.6	3
264	Trends in Incidence and Survival of Multiple Myeloma in the Netherlands in the Last Two Decades. Results From a National Population Based Study. <i>Blood</i> , 2011, 118, 5071-5071.	0.6	30
265	Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN. <i>Blood</i> , 2011, 118, 633-633.	0.6	7
266	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. <i>Blood</i> , 2011, 118, 996-996.	0.6	3
267	A High-Risk Survival Classifier for Multiple Myeloma. <i>Blood</i> , 2011, 118, 1800-1800.	0.6	0
268	Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial. <i>Blood</i> , 2011, 118, 332-332.	0.6	0
269	Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. <i>Blood</i> , 2011, 118, 1377-1377.	0.6	0
270	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. <i>Blood</i> , 2011, 118, 3989-3989.	0.6	0

#	ARTICLE	IF	CITATIONS
271	A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. <i>Blood</i> , 2010, 115, 1113-1120.	0.6	271
272	Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. <i>Blood</i> , 2010, 116, 2543-2553.	0.6	286
273	Dealing with Neuropathy in Plasma-Cell Dyscrasias. Hematology American Society of Hematology Education Program, 2010, 2010, 423-430.	0.9	31
274	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	0.8	358
275	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. <i>Lancet Oncology</i> , The, 2010, 11, 1086-1095.	5.1	187
276	Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. <i>Lancet Oncology</i> , The, 2010, 11, 1057-1065.	5.1	204
277	Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3160-3166.	0.8	263
278	Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach. <i>Blood</i> , 2010, 116, 3046-3046.	0.6	4
279	Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. <i>Blood</i> , 2010, 116, 1941-1941.	0.6	3
280	Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma: Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib. <i>Blood</i> , 2010, 116, 304-304.	0.6	1
281	Immunophenotypic Analysis of Myeloma Precursors: Antigens for Therapeutic Targeting. <i>Blood</i> , 2010, 116, SCI-5-SCI-5.	0.6	0
282	Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial. <i>Blood</i> , 2010, 116, 445-445.	0.6	0
283	Reply to C.A. Dasanu et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2294-2296.	0.8	3
284	High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2009, 361, 1235-1248.	13.9	745
285	Lenalidomide plus dexamethasone is effective in multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 247-248.	12.5	4
286	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a doseâ€modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.	1.2	289
287	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 147, 531-534.	1.2	27
288	Phase III Trials for Multiple Myeloma in Northern Europe. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S39.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Thalidomide/dexamethasone in myeloma: a double-edged sword. <i>Blood</i> , 2009, 113, 3394-3394.	0.6	0
290	Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1794-1794.	0.6	18
291	Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 1800-1800.	0.6	1
292	Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.. <i>Blood</i> , 2009, 114, 1876-1876.	0.6	4
293	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009, 114, 2878-2878.	0.6	18
294	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. <i>Blood</i> , 2009, 114, 743-743.	0.6	6
295	Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.. <i>Blood</i> , 2009, 114, 2208-2208.	0.6	0
296	Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1790-1790.	0.6	0
297	MicroRNAs Are Differentially Expressed Among Cytogenetic Subgroups in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2833-2833.	0.6	0
298	Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone.. <i>Blood</i> , 2009, 114, 4778-4778.	0.6	0
299	Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.. <i>Blood</i> , 2009, 114, 2886-2886.	0.6	0
300	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. <i>Cancer</i> , 2008, 112, 1529-1537.	2.0	68
301	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 46-53.	1.2	94
302	Interleukin-6 and Interleukin-1 enhancement of GM-CSF-dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2008, 77, 515-522.	1.2	13
303	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	0.6	294
304	Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4784-4790.	0.8	244
305	Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. <i>Blood</i> , 2008, 112, 4924-4934.	0.6	65
306	Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 867-867.	0.6	11

#	ARTICLE	IF	CITATIONS
307	Microparticle-Associated Tissue Factor Activity and Venous Thrombosis in Multiple Myeloma.. Blood, 2008, 112, 1812-1812.	0.6	0
308	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. Journal of Clinical Oncology, 2007, 25, 3892-3901.	0.8	607
309	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood, 2007, 110, 3557-3560.	0.6	485
310	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood, 2007, 109, 3177-3188.	0.6	379
311	Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica, 2007, 92, 928-935.	1.7	73
312	Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60â€¦years and older express adverse prognostic value: results from a prospective clinical trial. British Journal of Haematology, 2007, 136, 96-105.	1.2	59
313	CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of Hematology, 2007, 86, 329-337.	0.8	96
314	Gene Expression Profiles as Prognostic Factors in Patients with Multiple Myeloma Treated with Conventional Versus Novel Agents in Correlation with Outcome.. Blood, 2007, 110, 3173-3173.	0.6	0
315	ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clinical Pharmacology and Therapeutics, 2006, 80, 427-439.	2.3	43
316	First Report of the HOVON 45: A Phase II Study with Rituximab, High Dose Ara-C and Autologous Stem Cell Transplantation in the Primary Treatment of Mantle Cell Lymphoma.. Blood, 2006, 108, 2734-2734.	0.6	2
317	The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.. Blood, 2006, 108, 246-246.	0.6	9
318	The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood, 2005, 106, 2646-2654.	0.6	161
319	European Myeloma Network: The Value of Collaborative Research. Acta Haematologica, 2005, 114, 14-17.	0.7	2
320	International Staging System for Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 3412-3420.	0.8	2,404
321	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	13.9	2,356
322	Six Courses of Intensified CHOP Plus G-CSF Compared to Eight Courses of Standard CHOP in Patients with Intermediate-Risk Aggressive Non-Hodgkin Lymphoma Results of a Prospective Randomized HOVON Trial.. Blood, 2005, 106, 14-14.	0.6	8
323	HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.. Blood, 2005, 106, 424-424.	0.6	24
324	Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia.. Leukemia Research, 2004, 28, 1057-1067.	0.4	38

#	ARTICLE	IF	CITATIONS
325	Immunophenotyping as a guide for targeted therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 629-644.	0.7	6
326	Partially T-Cellâ€Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM. <i>Journal of Clinical Oncology</i> , 2003, 21, 1728-1733.	0.8	80
327	Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. <i>Blood</i> , 2003, 101, 2144-2151.	0.6	146
328	Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. <i>Cancer Research</i> , 2002, 62, 7298-304.	0.4	66
329	MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1997, 99, 76-83.	1.2	87
330	Malignant histiocytosis: A reassessment of cases formerly classified as histiocytic neoplasms and review of the literature. <i>Medical and Pediatric Oncology</i> , 1995, 25, 1-7.	1.0	40
331	Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 238-242.	1.1	59
332	In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. <i>British Journal of Haematology</i> , 1991, 79, 589-594.	1.2	23
333	Overexpression of theMDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. <i>International Journal of Cancer</i> , 1990, 45, 263-268.	2.3	125